 Epithelial cancer patients who are progressing on or after standard therapy or for whom no standard therapy exists. Catumaxomab trifunctional anti-EpCAM x anti-CD3 antibodyCatumaxomab will be administered i.v. once weekly qwk with each infusion lasting for 6 hours. The starting dose for catumaxomab will be 2 μg. The dose escalation schedule is based on a Modified Fibonacci Schedule with the following dose cohorts: 2 μg, 4 μg, 7 μg, 10 μg, 14 μg and 19 μg qwk corresponding to dose increments of 100, 75, 43, 40 and 36 respectively of the previous dose. Subsequent dose levels will correspond to dosing increments of about 30, e.g. 25, 33, 43, 56 μg. After completion of the DLT period, all patients will be offered continuation of catumaxomab treatment at the same dose until disease progression or death, whichever occurs first. The maximum length of treatment, however, will be restricted to an additional 12 weeks after the DLT period - resulting in a maximum treatment duration of 16 weeks total. 